Predicting survival in early hepatocellular carcinoma

Ryder, S.
March 2005
Gut;Mar2005, Vol. 54 Issue 3, p328
Academic Journal
The article presents information related to predicting survival in early hepatocellular carcinoma. Over the past decade, non-surgical therapies for hepatocellular carcinoma (HCC) occurring on a background of cirrhosis have been established as effective. Hepatic arterial chemoembolisation has a proven survival advantage in selected patient groups, and there is now strong evidence that ablative therapies, both percutaneous alcohol injection and radiofrequency ablation, have survival benefit. In addition, HCC incidence is increasing in the Western world, mainly due to the hepatitis C epidemic and this cancer now has an increasing impact on health services.


Related Articles

  • Immunohistochemical Detection of HCV in Cirrhosis, Dysplastic Nodules, and Hepatocellular Carcinomas with Parallel-Tissue Quantitative RT-PCR. Rullier, Anne; Trimoulet, Pascale; Urbaniak, Rosa; Winnock, Maria; Zauli, Daniela; Ballardini, Giorgio; Rosenbaum, Jean; Balabaud, Charles; Bioulac-Sage, Paulette; Bail, Brigitte Le // Modern Pathology;May2001, Vol. 14 Issue 5, p496 

    Hepatitis C virus is a major risk factor for hepatocarcinogenesis in humans. In situ detection of the virus in early sequential lesions of hepatocarcinogenesis could provide information about the role of the virus in the transformation and promotion process. Parallel in situ detection of HCV...

  • High α-Fetoprotein Level in HCV- Related Nodular Liver Cell Dysplasia. Ng Fook-Hong; Chow Kai-Chiu; Cheng Chi-Sing; Kng Carolyn; Ng Wing-Fung; Wong Benjamin Chun-Yu // American Journal of Gastroenterology;Aug1999, Vol. 94 Issue 8, p2296 

    The diagnosis of hepatocellular carcinoma is generally made in patients with a mass lesion in the cirrhotic liver if the α-fetoprotein level is >1,000 ng/L. Other causes of elevation of α-fetoprotein to this extreme degree include nonseminomatous germ cell tumor and hepatic metastasis....

  • Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Averhoff, Francisco M.; Glass, Nancy; Holtzman, Deborah // Clinical Infectious Diseases;Jul2012 Supplement 1, Vol. 55 Issue suppl_1, pS10 

    An estimated 2%–3% of the world's population is living with hepatitis C virus (HCV) infection, and each year, >350 000 die of HCV-related conditions, including cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific...

  • HCC risk persists 8 years after HCV eradication.  // Infectious Disease News;Jun2013, Vol. 26 Issue 6, p36 

    The article discusses the results of a study which concluded that patients with hepatitis C-induced liver cirrhosis have a long-term risk for hepatocellular carcinoma of up to 8 years after sustained virological response to antiviral therapy.

  • Hepatitis C: Symptoms.  // Hepatitis C (National Institute of Allergy/Infectious Disease);2009, p5 

    The article offers information on the symptoms of hepatitis C. It mentions that the patients suffering from hepatitis C have abdominal pain, loss of appetite and nausea or vomiting and symptoms of acute hepatitis C appear 6 to 12 weeks after exposure to the virus. It further mentions that in...

  • Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis. Velosa, José; Serejo, Fátima; Marinho, Rui; Nunes, Joana; Glória, Helena // Digestive Diseases & Sciences;Jun2011, Vol. 56 Issue 6, p1853 

    Background: The effect of a sustained virological response (SVR) to interferon (IFN) on clinical outcomes of hepatitis C virus (HCV)-related cirrhosis is controversial. Aims: Evaluate the effect of SVR to IFN on the incidence of hepatocellular carcinoma (HCC) and mortality in patients with...

  • Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. Nahon, Pierre; Sutton, Angela; Rufat, Pierre; Simon, Chantal; Trinchet, Jean-Claude; Gattegno, Liliane; Beaugrand, Michel; Charnaux, Nathalie; Rodrigo, Luis; Shimada, Mitsuo; Einarsson, Curt // World Journal of Gastroenterology;2/7/2008, Vol. 14 Issue 5, p713 

    AIM: To explore the influence of polymorphisms in genes encoding for the chemokines Stromal cell-Derived Factor-1 (SDF-1)/CXCL12 and Monocyte Chemotactic Protein-1 (MCP-1) /CCL2, or for the chemokine receptor CCR5 on the risks of liver-related death and hepatocellular carcinoma (HCC) occurrence...

  • The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Goodgame, Boone; Shaheen, Nicholas J.; Galanko, Joseph; El-Serag, Hashem B. // American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2535 

    : ObjectivesIn persons infected with hepatitis C virus (HCV), the incidence of cirrhosis and hepatocellular carcinoma (HCC) can be estimated by examining over time entire cohorts with known onset of HCV infection. We performed a systematic review of the literature to identify and to analyze...

  • High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study. Ming-Lung Yu; Chia-Yen Dai; Shinn-Cherng Chen; Li-Po Lee; Ming-Yen Hsieh; Zu-Yau Lin; Ming-Yuh Hsieh; Liang-Yen Wang; Jung-Fa Tsai; Wen-Yu Chang; Wan-Long Chuang // BMC Infectious Diseases;2005, Vol. 5 Issue 1, p27 

    Background: Interferon-alpha monotherapy is effective in less than one-third patients with chronic hepatitis C. The dose-effect, tolerability and durability of interferon-alpha treatment and its long-term effect on the prevention of cirrhosis and hepatocellular carcinoma in naive Taiwanese...


Read the Article


Sign out of this library

Other Topics